Related news:CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
CymaBay Therapeutics
Bookmark
ShareCymaBay Therapeutics is a company. It is located in Newark, the United States and was founded in 1991. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Newark
- state: CA
- country: United States
- sector: Health Care
- industry: Biotechnology
- foundation year: 1991
- CEO: Sujal A. Shah
- CEO gender: Male
Classified as: organization
Business
CymaBay Therapeutics is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 202.3M $
- Debt: 79.8M $
- Employees: 59 people
- Free cash flow: -41471800 $
- Market cap: 296.3M $
- Revenues:
Try Pro to see estimates
Stocks from CymaBay Therapeutics:
Talking Points:
- CymaBay Therapeutics
- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease
- condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Learn more about talking points
